- Home
- GPUS vs MYNZ Comparison
GPUS vs MYNZ Comparison
Compare GPUS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPUS
- MYNZ
- Stock Information
- Founded
- GPUS 1969
- MYNZ 2021
- Country
- GPUS United States
- MYNZ Germany
- Employees
- GPUS N/A
- MYNZ N/A
- Industry
- GPUS
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- GPUS
- MYNZ Health Care
- Exchange
- GPUS NYSE
- MYNZ Nasdaq
- Market Cap
- GPUS 4.8M
- MYNZ 5.5M
- IPO Year
- GPUS 1996
- MYNZ 2021
- Fundamental
- Price
- GPUS $1.34
- MYNZ $1.81
- Analyst Decision
- GPUS
- MYNZ Buy
- Analyst Count
- GPUS 0
- MYNZ 2
- Target Price
- GPUS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- GPUS 8.9M
- MYNZ 128.3K
- Earning Date
- GPUS 08-15-2025
- MYNZ 07-15-2025
- Dividend Yield
- GPUS N/A
- MYNZ N/A
- EPS Growth
- GPUS N/A
- MYNZ N/A
- EPS
- GPUS N/A
- MYNZ N/A
- Revenue
- GPUS $93,318,000.00
- MYNZ $893,991.00
- Revenue This Year
- GPUS N/A
- MYNZ $26.06
- Revenue Next Year
- GPUS N/A
- MYNZ $4.97
- P/E Ratio
- GPUS N/A
- MYNZ N/A
- Revenue Growth
- GPUS N/A
- MYNZ N/A
- 52 Week Low
- GPUS $1.23
- MYNZ $1.34
- 52 Week High
- GPUS $11.73
- MYNZ $22.14
- Technical
- Relative Strength Index (RSI)
- GPUS N/A
- MYNZ 35.61
- Support Level
- GPUS N/A
- MYNZ $1.35
- Resistance Level
- GPUS N/A
- MYNZ $1.46
- Average True Range (ATR)
- GPUS 0.00
- MYNZ 0.09
- MACD
- GPUS 0.00
- MYNZ 0.04
- Stochastic Oscillator
- GPUS 0.00
- MYNZ 62.93
About GPUS HYPERSCALE DATA INC
Hyperscale Data Inc, formerly Ault Alliance Inc is a diversified holding company. It operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including oil exploration, crane services, defense/aerospace, industrial, automotive, medical/biopharma, consumer electronics, hotel operations and textiles. The company has six reportable segments: Energy and Infrastructure; Technology and Finance; Sentinum, Inc.; GIGA; TurnOnGreen; ROI; and Ault Global Real Estate Equities, Inc.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.